This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Retain Change Healthcare (CHNG) Stock
by Zacks Equity Research
Change Healthcare (CHNG) continues to benefit from strategic deals. However, intense competition remains a woe.
Baidu (BIDU) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Baidu's (BIDU) first-quarter results are expected to reflect the AI business's strength and gains from expanding autonomous driving efforts.
Dell Technologies (DELL) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Dell Technologies' (DELL) first-quarter fiscal 2023 performance is expected to reflect strong PC sales and solid growth in servers amid supply-chain constraints and higher component costs.
4 Stocks to Buy on Surge in Cloud Infrastructure Spending
by Ritujay Ghosh
A rapid rise in spending on cloud infrastructure services is helping companies like 8x8, Inc. (EGHT), Duck Creek Technologies, Inc. (DCT), Paycom Software, Inc. (PAYC) and Veeva Systems Inc. (VEEV).
VMware (VMW) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
VMware's (VMW) first-quarter fiscal 2023 performance is likely to have benefited from a strong portfolio and an expanding partner base.
BOX Gears Up to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
BOX's first-quarter fiscal 2023 results are likely to reflect gains from the growing adoption of content cloud solutions. Also, growing efforts toward product innovation might have been a tailwind.
What's in the Cards for Agilent Technologies' (A) Q2 Earnings?
by Zacks Equity Research
Agilent Technologies' (A) fiscal second-quarter results are expected to reflect portfolio strength and momentum across all segments.
PerkinElmer (PKI) Boosts Genomic Testing Portfolio With urWGS
by Zacks Equity Research
PerkinElmer's (PKI) urWGS will improve outcomes for critically ill patients in NICUs and PICUs.
Can Veeva (VEEV) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Veeva (VEEV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why You Should Hold on to DexCom (DXCM) Stock Now
by Zacks Equity Research
DexCom (DXCM) continues to benefit from a solid product portfolio and a strong international presence. However, supply constraints remain a woe.
BD (BDX) Introduces New Molecular Diagnostic Platform in US
by Zacks Equity Research
BD's (BDX) new fully-automated, high-throughput infectious disease molecular diagnostics platform in the United States to aid lab technicians in prioritizing higher value work.
Here's Why You Should Retain Cooper Companies (COO) Stock Now
by Zacks Equity Research
Cooper Companies (COO) continues to benefit from strength in its business segments.
Here's Why You Should Retain West Pharmaceutical (WST) Now
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.
GAN Limited (GAN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
GAN Limited (GAN) delivered earnings and revenue surprises of 10% and 11.23%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
BD (BDX) Extends Partnership to Boost Diagnostic Blood Collection
by Zacks Equity Research
BD (BDX) expands strategic partnership with Babson Diagnostics that will enable less invasive blood sample collection easier and patient-centric.
Here's Why You Should Hold on to Stryker (SYK) Stock for Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform, Mako, and broad product portfolio. However, pricing pressure weighs on it.
Here's Why You Should Retain Intuitive Surgical (ISRG) Stock
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to gain traction from the improving adoption of the da Vince Surgical System. Higher production costs are a woe.
Ziff Davis (ZD) Misses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Ziff Davis (ZD) delivered earnings and revenue surprises of -5.38% and 2.89%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
AudioEye (AEYE) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
AudioEye (AEYE) delivered earnings and revenue surprises of 25.58% and 1.77%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
QuinStreet (QNST) Misses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
QuinStreet (QNST) delivered earnings and revenue surprises of -18.18% and 1.21%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Veeva Systems (VEEV) Sees Wider Adoption of Its Development Cloud
by Zacks Equity Research
Adoption of Veeva Systems' (VEEV) cloud applications is likely to significantly boost its Veeva Development Cloud business.
Masimo's (MASI) New Product Expansion to Boost Patient Outcome
by Zacks Equity Research
Masimo's (MASI) latest feature additions to its telehealth for Patient SafetyNet are likely to significantly improve patient outcomes.
Veeva (VEEV) Beats on Q4 Earnings, Narrows '23 Revenue View
by Zacks Equity Research
Veeva Systems' (VEEV) fiscal Q4 results reflect impressive performances by both of its segments.
Veeva Systems (VEEV) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Veeva (VEEV) delivered earnings and revenue surprises of 2.27% and 1.15%, respectively, for the quarter ended January 2022. Do the numbers hold clues to what lies ahead for the stock?
Looking for that Perfect 5-Year Earnings Chart?
by Tracey Ryniec
Think that the pandemic has upended most companies' earnings surprise track records? Think again.